Importance of Bcl-2 with respect to hematologic malignancies is indirectly documented by the fact that targeting of Bcl-2, by ABT-199, but not Bcl-XL is associated with promising clinical results in CLL and AML [14]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.